Bitcoin and Stablecoins Fuel Rapid Growth in Gray-Market Peptide Sales

• Peptide crypto transactions jumped 159% as global demand accelerated.
• Large vendors increasingly preferred stablecoins over Bitcoin for stability.
• Testing spending declined while safety concerns grew across markets.

Cryptocurrency has become the financial backbone of the gray-market peptide trade, with Bitcoin and stablecoins supporting a surge in sales across an industry that has now surpassed a $100 million annual run rate, according to a new report from Chainalysis. The blockchain analytics firm reported that peptide-related cryptocurrency transactions reached $32 million during the first quarter of 2026, representing a 159% increase from the $12 million recorded in the previous quarter as more buyers and suppliers moved toward digital assets for cross-border payments.

According to Chainalysis, growing interest in peptides has transformed what was once a niche market into a rapidly expanding global industry, with demand increasing alongside the popularity of GLP-1 drugs such as Ozempic and Wegovy. Peptides, which serve as building blocks of proteins, are widely promoted across health, fitness, and wellness communities for a variety of purposes, including weight management, muscle recovery, and general well-being.

As demand accelerated, suppliers operating outside traditional pharmaceutical channels expanded their reach to international customers, while cryptocurrency emerged as a preferred payment option for both large-scale vendors and retail buyers. Chainalysis noted that many suppliers are based in China, where certain chemical manufacturers face difficulties accessing conventional banking services, making digital assets a practical alternative for processing transactions and settling payments across multiple jurisdictions.

Also Read: Virtuals Moves $700M to Chainlink CCIP as LayerZero Migration Trend Grows

Larger Vendors Favor Stablecoins as Crypto Usage Expands

Chainalysis found that payment preferences vary significantly depending on the size of the supplier and the volume of transactions being processed through cryptocurrency networks. While Bitcoin remains widely used throughout the sector, larger vendors receiving deposits averaging more than $1,000 increasingly favor stablecoins because they offer protection from market volatility while facilitating larger inventory purchases and supply chain transactions.

Researchers observed that top-tier peptide vendors have adopted a more professional approach to on-chain finance, with many businesses managing digital asset exposure in ways similar to established commercial operations. Beyond payment trends, the report also highlighted a growing gap between peptide purchases and spending on independent product testing services.

Before the recent surge in sales activity, many peptide buyers regularly used the services of Janoshik, a Czech-based laboratory that performs chemical purity testing for products purchased from overseas suppliers. However, Chainalysis estimated that testing expenditure per buyer has fallen by roughly 88% to just $8, even though Janoshik is currently handling more testing requests than at any other point in its history due to the growing number of market participants.

The report suggested that many new buyers entering the market may be purchasing peptide products without dedicating comparable resources to quality verification, creating additional concerns around product safety and consumer awareness.

Chainalysis also identified links between portions of the peptide industry and organizations previously associated with illicit chemical sales. One example involved Shanghai Sigma Audley, a supplier that reportedly generated substantial cryptocurrency revenue from fentanyl precursor sales before expanding into peptide distribution.

Before shifting part of its operations toward peptides, the supplier received at least $1 million in Bitcoin and $3.59 million in stablecoins, according to data cited by Chainalysis.

Safety Concerns Grow Alongside Market Expansion

Chainalysis warned that the expanding peptide market increasingly attracts consumers who have limited experience with both cryptocurrency and unregulated pharmaceutical products, creating risks as transaction volumes continue rising across the sector. The firm concluded that Bitcoin and stablecoins now play a central role in supporting peptide commerce, while the combination of rapid growth, lower testing expenditure, and greater accessibility continues drawing attention to the industry’s evolving risk profile.

According to Chainalysis, cryptocurrency has moved from being a payment alternative to becoming a core component of the gray-market peptide economy. As Bitcoin and stablecoin adoption continues expanding across the supply chain, the industry’s growth is increasingly being accompanied by concerns surrounding consumer safety, product verification, and regulatory oversight.

Also Read: Strategy Chairman Saylor Links Bitcoin Drop to Massive AI Funding

The post Bitcoin and Stablecoins Fuel Rapid Growth in Gray-Market Peptide Sales appeared first on 36Crypto.